Registro completo |
Provedor de dados: |
BJPS
|
País: |
Brazil
|
Título: |
Efficacy of secnidazole-diminazene aceturate combination therapy in the late treatment of Trypanosoma brucei brucei infection in dogs
|
Autores: |
Eke,Ifeanyi Gabriel
Ezeh,Ikenna Onyema
Ezeudu,Terry Adaeze
Eze,Ukamaka Uchenna
Anaga,Aruh Ottah
Onyeyili,Patrick Azubuike
|
Data: |
2020-01-01
|
Ano: |
2020
|
Palavras-chave: |
Secnidazole
Diminazene aceturate
Combination therapy
Trypanosomosis
Dogs
Relapse
|
Resumo: |
This study evaluated the efficacy of combination therapy of secnidazole-diminazene aceturate (SEC-DA) in late treatment of dogs experimentally infected with relapsing strain of Trypanosoma brucei brucei. Fifteen dogs were randomly assigned to 5 groups (A - E) of 3 per group. Group A (uninfected untreated), B (infected untreated), C (infected and treated with DA (3.5 mg/kg) IM stat), D (infected and treated with secnidazole (SEC) (100 mg/kg) orally for 5 days and DA (3.5 mg/kg) IM stat), E (infected and treated with SEC (200 mg/kg) orally for 5 days and DA (3.5 mg/kg) IM stat). Dogs were infected intraperitoneally with 5 x 105 trypanosomes and treatment started 14 days post-infection. Data on parasitaemia, hematology and rectal temperature were recorded. Parasitaemia cleared within 3 days in all the SEC-DA treated dogs and there was no relapse parasitaemia. Parasitaemia did not clear in DA monotherapy dogs. All the SEC-DA treated dogs showed significantly (P < 0.05) higher leucocyte counts, red blood cell count, packed cell volume, hemoglobin concentration and lower rectal temperature than DA monotherapy. It was, therefore, concluded that SEC-DA combination is therapeutically more efficacious than DA monotherapy in the late treatment of T.b. brucei infection in dogs.
|
Tipo: |
Info:eu-repo/semantics/article
|
Idioma: |
Inglês
|
Identificador: |
http://www.scielo.br/scielo.php?script=sci_arttext&pid=S1984-82502020000100521
|
Editor: |
Universidade de São Paulo, Faculdade de Ciências Farmacêuticas
|
Relação: |
10.1590/s2175-97902019000318042
|
Formato: |
text/html
|
Fonte: |
Brazilian Journal of Pharmaceutical Sciences v.56 2020
|
Direitos: |
info:eu-repo/semantics/openAccess
|